Investor
Ideas #Potcasts, #Cannabis News and #Stocks on the Move; Episode 432 (CSE: $LIB.C) (NASDAQ: $NEPT) (TSX: $NEPT.TO) (TSXV: $N.V) (CSE: $BILZ.C) (NYSE: $IFF) (TSXV: $NRTH.V) (TSX: $AVCN.TO)
Delta, Kelowna, BC, June 22, 2020 (Investorideas.com Newswire)
www.Investorideas.com, a global news source covering leading sectors including
marijuana and hemp stocks and its potcast site, www.potcasts.ca release today’s podcast edition of cannabis news and stocks to watch plus insight
from thought leaders and experts.
Listen to the podcast:
Read this in full
at https://www.investorideas.com/news/2020/cannabis-potcasts/06221LIB-NEPT-N-BILZ-IFF-NRTH-AVCN.asp
Today’s podcast overview/transcript:
Good
afternoon and welcome to another episode of Investorideas.com
"Potcast" featuring cannabis news, stocks to watch as well as
insights from thought leaders and experts.
In
today’s podcast we look at a few public company announcements.
Liberty
Leaf Holdings Ltd. (CSE:
LIB)(OTC:
LIBFF) announced that it
has entered into an agreement with Nova Mentis Biotech Corp., pursuant to which
LIB will acquire, by way of share exchange, 100 per cent of all of the issued
and outstanding securities of NOVA.
Highlights of the Transaction:
● LIB
gains NOVA's current net cash balance of approximately $1.2M CDN;
● Adds
synergistic accompaniment to LIB's operating and licensed cannabis assets
within the health and wellness sector;
● Bolsters
roster of personnel who possess experience within scientific and R&D
community; and
● Provides
opportunity for intellectual property creation as NOVA advances its research
mandate.
NOVA is a research and development
driven company that is focused on investigating the anti-inflammatory effects
of psilocybin in underexplored metabolic indications such as obesity and
diabetes. NOVA is of the view that its
target indications represent vast and growing segments of the population. For example, in the United States, more than
10.5% of the population has Diabetes, which represents approximately 34.2
million people. Diabetes treatment can
bare significant economic burden to patients with the average out of pocket
monthly cost being estimated at $360 USD.
According to a report by Fortune Business Insights, the global diabetes
drug market size was valued at USD $48 Billion in 2018 and is projected to
reach USD $78 Billion by 2026.
Increasing societal prevalence of sedentary lifestyles coupled with vast
access to inexpensive and nutritionally void food options are likely to
contribute to further incidence of obesity and diabetes in the future. According to the National Center for Health
Statistics, 39.8% of the US population aged 20 and over were considered obese
in 2016, with an additional 31.8% being considered overweight. Obese individuals have a significantly higher
incidence of depression (close to 30%) compared to the general population.
Bidirectionally, according to the CDC, about 43% of depressed people are obese.
The strong therapeutic potential of
psilocybin has emerged for a wide range of disorders, primarily mental health
related. NOVA is focusing on a cohort group that has been very difficult to
treat, both acutely and also in a sustainable way. This group of individuals
have an overlap in two widespread and very important indications, obesity and
depression. These comorbid conditions share inflammation as an important common
mediator. NOVA's pre-clinical scientific study thus far is focused on targeting
the gut-brain axis to modulate inflammation in this context. The aim is to
utilize the unique properties of psilocybin to address both physiological and
behavioural factors in obesity and comorbid depression.
NOVA was founded and is led by Dr.
Aylia Mohammadi. Dr. Mohammadi obtained her PhD in Biological Physics from the
Donnelly Centre for Cellular & Biomolecular Research at the University of
Toronto, and subsequently completed a postdoctoral fellowship at the
Lunenfeld-Tanenbaum Research
Institute at Mount Sinai Hospital in Toronto. Aylia is a TEDx speaker, and has
presented her work at international conferences. Her graduate training was
inherently multidisciplinary, integrating techniques in molecular biology,
neuroscience, and genetics. For her postdoctoral research, she examined
underlying molecular mechanisms of inflammatory bowel disease, giving her a
strong and relevant background to guide NOVA's scientific aims.
"Recent scientific advancement
coupled with shifting opinions amongst, both the medical and general
communities, at large regarding psychedelics including psilocybin make it a
sector worthy of investment," stated Will Rascan, President and CEO of
LIB. "Since our shift into cannabis
in 2014, and our subsequent investment in Just Kush Enterprises Ltd, - now a
holder of three Health Canada Cannabis Licenses – we have focused on emerging
trends and shifting public awareness of natural based compounds for health and
wellness, I believe this acquisition compliments our current legal cannabis
portfolio and provides stakeholders with an early entrance in a new flourishing
market."
Neptune
Wellness Solutions Inc. (NASDAQ:
NEPT) (TSX:
NEPT), a diversified and fully integrated health and
wellness company, announced today
an expansion of its branded hand sanitizer product line.
Developed by Neptune Health &
Wellness Innovations, in partnership with International
Flavors & Fragrances (NYSE:
IFF),
the expanded product line consists of six new scented varieties, including
Garden Mint, Fresh Linen, Orange Hibiscus, Eucalyptus, Fresh Lemon & Tea
Tree, and Lavender. Neptune's products are natural, plant-based sanitizers made
with a specialized blend of essential oils, aloe vera and fruit extract.
The expanded hand sanitizer product
line is expected to launch in July in the club store channel through one of the
largest retailers in the world. Neptune's partnership with IFF allows for rapid
product development and delivery to retailers to ensure products are on the
shelf and available to consumers. The
Company expects expanded hand sanitizer revenues to be realized beginning in
the second quarter of fiscal year 2021.
"We believe natural,
plant-based products are the future as consumers pay increased attention to
their health and wellness and use hand sanitizer products more frequently to
prevent the spread of germs and bacteria," said Michael Cammarata, Chief
Executive Officer of Neptune Wellness Solutions. "The expansion of our hand sanitizer
product line through our partnership with IFF offers consumers a better
experience with a variety of great scents, as well as essential oils and aloe
vera to promote skin health. We look
forward to increasing our distribution nationwide through our retail
partnerships."
Nicolas Mirzayantz, IFF Divisional
CEO, Scent, said, "We are proud to partner with Michael and his team on
this timely and important product line.
It is exciting to bring the talents of our perfumers and IFF's
exceptional portfolio of natural and sustainable ingredients to create
fragrances that help make keeping safe a better experience for consumers."
Neptune Health & Wellness
Innovations is rapidly bringing new products to market to address market demand
for critical health and wellness products such as the Neptune Halo oximeter,
the Neptune Air non-contact thermometer, as well as hand sanitizer products and
other innovations in development.
Namaste
Technologies Inc. (TSXV:
N)
(OTC:
NXTTF), a leading platform for cannabis products,
accessories, and education, today
announced CannMart Inc., a wholly owned subsidiary,
has been granted an exclusive license by IGNITE
International Brands, Ltd. (CSE:
BILZ) (OTCQX:
BILZF) to utilize certain brand trademarks on cannabis-based
products for sale in the legal Canadian marketplace. In addition, CannMart has
received approval from Alberta Gaming, Liquor & Cannabis and the Ontario
Cannabis Retail Corporation operating as the Ontario Cannabis Store to begin
offering Cannabis 2.0 products.
"Our agreement to become the
exclusive distributor of IGNITE products in Canada is an important milestone
for the company and positively reflects on our value proposition," said
Meni Morim, CEO of Namaste Technologies. "CannMart continues to
demonstrate its ability to grow its sales distribution channels in the Canadian
market and this is attracting the attention of well-established brands like
IGNITE. We place a high value on our relationships with these brands as it is
our belief that brand recognition will be a major driver of growth as the legal
industry matures and transitions to consumer-packaged goods. The opportunity
for CannMart to be the exclusive distributor for IGNITE in Canada reinforces
our position in the competitive cannabis market as consumers gravitate towards
brands that are well known and trusted for their quality."
"The listing of Cannabis 2.0
products for the provinces of Ontario and Alberta is an important achievement
and opens meaningful additional revenue channels. The Cannabis 2.0 market is a
large addressable market and the approval to list our products in Alberta and
Ontario, with more than 450 and 90 cannabis stores respectively, represents a
substantial increase in the addressable market for CannMart. We expect to
continue our recent sales success of cannabis products from premium brands,
like IGNITE, through CannMart.com and throughout our network of government
partners and retailers."
"Canada is an important market
for IGNITE International Brands and CannMart has shown its ability to deliver
high quality products to our target market," said Lester Lee, President of
IGNITE. "The awareness of the IGNITE brand continues to build throughout
Canada and our product sales continue to grow. The team at CannMart has been
instrumental and has proven their competency to navigate the regulations within
the legal market. We trust that our brand can be nurtured in accordance with
our high standards and together we can continue to build on our early success
as we look to grow market share."
Further to the news release of March
20, 2020, CannMart and IGNITE have amended the licensing agreement to add
exclusivity to the markets in Canada. The revised agreement grants CannMart an
exclusive licence to use certain IGNITE brand trademarks on legal cannabis-based
products (the "IGNITE Products") in consideration for certain royalty
payments. CannMart's introduction of IGNITE cannabis products has been welcomed
by its customers and demand has continued to grow.
CannMart's listing of its first
Cannabis 2.0 products in the provinces of Alberta and Ontario are now approved
by both jurisdictions. CannMart's first offering will be a variety of vape
cartridges. The AGLC is responsible for regulating and distributing cannabis to
Alberta's licensed retailers and the sole legal online retailer for
recreational cannabis at www.albertacannabis.org. The
OCS is the sole legal online retailer and wholesaler for recreational cannabis
for Canada's most populous province.
48North
Cannabis Corp. (TSXV:
NRTH) reported a
successful first week of planting on Good:Farm, one of Canada's first and
largest outdoor cannabis facilities.
Following the first season for
licensed outdoor cultivation in Canada, 48North enters the upcoming season with
improved know how, as well as operational and structural improvements to ensure
that Good:Farm helps meet the steady demand for 48North products and positions
itself to take advantage of opportunities for contract manufacturing
partnerships.
"48North's commitment to
cultivating outdoor, organic, sun-grown cannabis positions us to deliver the
products our customers deserve in 2020," said Charles Vennat, CEO of
48North. "Without question, outdoor cultivation has been a game changer
for the industry in terms of cost and quality. Last year, the Company learned
important operational lessons in our season that will inform our 2020 approach.
Our early mover advantage positions us to thrive in this space, while
continuing to drive down cultivation costs below last year's benchmark of $0.25
per gram."
48North has taken the planting
"off season" to focus on critical operational improvements at
Good:Farm, including:
● Construction
of a state-of-the-art drying facility on site, purpose built to be adapted for
indoor cultivation in the winter (48North's licence amendment application was
submitted for the drying facility on May 8th and early conversations with
Health Canada leave the Company confident in its ability to receive approval in
time for harvest);
● Leveraging
genetics that succeeded outdoors in the first season at Good:Farm, through an
in-house genetic breeding program,
● Introducing
clone and tissue culture cultivation to Good:Farm, in addition to the Company's
experience with seed stock;
● Expanding
beyond Good:Farm's organic farming processes, with a specific focus on
regenerative practices to nurture more resilient soils for nutrient-rich crops,
this includes the consideration of the longevity and fertility of our farm;
● Recruiting
new management with local know how and successful outdoor cannabis cultivation
experience; and
● Emphasizing
the Company's commitment to sustainability by eliminating single-use plastics
in the production process.
Good:Farm's inaugural planting
season demonstrated that high-quality, low cost cannabis for next generation
cannabis products is best grown on a farm. Popular strains and products already
on the market are the result of 48North's first harvest. The Company's added
experience and operational upgrades will position it to build on this momentum
and deliver on its initial vision of giving people the latitude to live well
through high-quality cannabis products.
Avicanna
Inc. (TSX:
AVCN) (OTCQX:
AVCNF), a biopharmaceutical company focused on the
development, manufacturing and commercialization of plant-derived
cannabinoid-based products, announced that on
July 21st, 2020 it will be hosting a virtual symposium titled "Medical
Cannabis 2.0" in partnership with Medical Cannabis by Shoppers. Patients
and health care practitioners globally can join the virtual symposium to learn
more about the potential advantages of medical cannabis and the advancement of
product offerings including Avicanna's RHO Phyto product offerings and advanced
cannabinoid research collaboration at the University of Toronto. In addition,
experts will discuss the pharmacology, safety, and dosing guidelines of medical
cannabis for therapeutic conditions.
This includes presentations on the, efficacy of cannabinoids for chronic
pain, anxiety, depression, and other comorbidities as well as an overview of
the patient pathway to Medical Cannabis by Shoppers.
"In this unprecedent time,
where patients and practitioners have many questions and are seeking
alternative and natural solutions, we are pleased to welcome you all to our
virtual symposium on medical cannabis. My talk on Common Medical Comorbidities
will discuss how medical cannabis can be used for the management of clinical conditions
that have common associated comorbidities of anxiety, depression and appetite
and sleep disorders. Alongside my colleagues and collaborators, we hope you
will find value in all our presentations and that they will provide important
information, as patients and health care practitioners seeking to learn more
about medical cannabis." – Dr. Amza Ali, Chief Medical Officer of Avicanna
Discussions will be led by
clinicians and scientists from the Avicanna team as well as from prestigious
Canadian academic and clinical research organizations including the University
of Toronto and University Health Network's Toronto General Hospital.
The agenda for the virtual symposium
is as follows:
● An
Introduction to Cannabinoids and Their Pharmacology – Dr. Ruth Ross (Professor
and Chair, Department of Pharmacology & Toxicology, Faculty of Medicine,
University of Toronto, Senior Scientist, Campbell Family Mental Health Research
Institute, CAMH)
● Advanced
Cannabinoid Research and drug development at the University of Toronto – Dr.
Pauric Bannigan (Post-Doctoral Fellow from Dr Christine Allen's laboratory at
the Leslie Dan Faculty of Pharmacy, University of Toronto)
● Medical
Cannabis 2.0 and Avicanna's RHO Phyto product offerings– Dr. Justin Grant
(Executive Vice President of Scientific Affairs, Avicanna)
● The
Potential of Cannabinoids for Chronic Pain – Dr. Hance Clarke (Staff
Anesthesiologist
Director Pain Services, Director Good Hope Ehlers Danlos Clinic, Medical Director of The Pain Research Unit, Department of Anesthesia and Pain Management, Toronto General Hospital, University Health Network, Associate Professor, Department of Anesthesia, University of Toronto)
Director Pain Services, Director Good Hope Ehlers Danlos Clinic, Medical Director of The Pain Research Unit, Department of Anesthesia and Pain Management, Toronto General Hospital, University Health Network, Associate Professor, Department of Anesthesia, University of Toronto)
● Anxiety,
Depression and Other Comorbidities in Patients to be Treated with Cannabinoids:
Implications for Optimal Care – Dr. Amza Ali (Chief Medical Officer, Avicanna)
● An
Introduction to Medical Cannabis by Shoppers Drug Mart – Neil D'Souza (Senior
Manager, Operations, Medical Cannabis by Shoppers Drug Mart)
● The
Future of Medical Cannabis Panel Discussion– (Aras Azadian, CEO of Avicanna
Inc. / Pat McCutcheon, CEO MediPharm Labs / Kaveh Kahen, CEO of Sigma
Analytics)
Investor ideas reminds all
listeners to read our disclaimers and disclosures on the Investorideas.com
website and that this podcast is not an endorsement to buy products or services
or securities. Investors are reminded all investment involves risk and possible
loss of investment.
Learn more about
our cannabis podcasts at https://www.investorideas.com/Audio/Potcasts.asp
Investorideas.com
podcasts are also available on iTunes,
Spotify, Google Play Music, Stitcher, Spreaker, YouTube via Spreaker, iHeartradio and Tunein.
Potcasts is now a certified
word mark Trademark on the blockchain through Cognate, Inc. CM
Certification-Registration Number: 10468217708
About Investorideas.com - News that
Inspires Big Investing Ideas
Investorideas.com
is a recognized news source publishing third party news, research and original
financial content. Learn about investing in stocks and sector trends with our
news alerts, articles, podcasts and
videos, looking at cannabis, crypto, AI and IoT, mining, sports biotech, water,
renewable energy and more. Investor Idea’s original branded content includes
the following podcasts and columns : Crypto Corner , Play
by Play sports and stock news column, Investor Ideas
Potcasts Cannabis News and Stocks on the Move podcast and
column, Cleantech
and Climate Change , Exploring
Mining the AI
Eye .
Disclaimer/Disclosure: Investorideas.com is a
digital publisher of third party sourced news, articles and equity research as
well as creates original content, including video, interviews and articles.
Original content created by investorideas is protected by copyright laws other
than syndication rights. Our site does not make recommendations for purchases
or sale of stocks, services or products. Nothing on our sites should be
construed as an offer or solicitation to buy or sell products or securities.
All investing involves risk and possible losses. This site is currently
compensated for news publication and distribution, social media and marketing,
content creation and more. Disclosure is posted for each compensated news
release, content published /created if required but otherwise the news was not
compensated for and was published for the sole interest of our readers and
followers. Contact management and IR of each company directly regarding
specific questions. More disclaimer info: https://www.investorideas.com/About/Disclaimer.asp Learn more about publishing your news release and our other
news services on the Investorideas.com newswire https://www.investorideas.com/News-Upload/ and tickertagstocknews.com
Global investors must adhere to regulations
of each country. Please read Investorideas.com privacy policy:
Investor Ideas does not condone the use of
cannabis except where permissible by law. Our site does not possess,
distribute, or sell cannabis products.
Contact Investorideas.com
800
665 0411
No comments:
Post a Comment